Answers are grounded in this paper and cite their sources.
Finds low-dose CT screening costs $81,000 per QALY gained for lung cancer, indicating cost-effectiveness depends heavily on implementation.
We estimated that screening for lung cancer with low-dose CT would cost $81,000 per QALY gained, but we also determined that modest changes in our assumptions would greatly alter this figure. The determination of whether screening outside the trial will be cost-effective will depend on how screening is implemented. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.).
No takes yet. Share an insight, caveat, or question.
Black et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: